SEATTLE, April 19, 2016 /PRNewswire/ -- Immunexpress Inc. today announced an exclusive collaboration with the Academic Medical Center (AMC) at the University of Amsterdam to characterize and clinically evaluate sepsis and sepsis-related biomarker signatures of the host response. This four-year collaboration with AMC's Prof. Dr. Tom van der Poll and his team will leverage the informatics expertise of both groups to further the clinical evaluation of proprietary biomarker signatures, as well as additional RNA, protein and epigenetic biomarkers. The collaboration is designed to advance Immunexpress's commercialization of a pipeline of host response products tailored for improved management of patients with sepsis and suspected of sepsis.
"Prof. van der Poll is one of the world's leading experts on sepsis, and we are excited to continue to work with him and his team under this new collaboration," said Dr. Roslyn Brandon, President and CEO of Immunexpress. "Through this partnership we hope to obtain a greater understanding of the host response to infection, sepsis and septic shock and to further aid in improved sepsis patient management."
Prof. Tom van der Poll, Principle Investigator at the Academic Medical Center, said, "The host immune response will provide us with a greater understanding of the mechanisms of sepsis pathology and potentially help to identify new diagnostic and treatment strategies for this endemic syndrome."
Under the terms of the agreement, Immunexpress will provide financial support, bioinformatic partnering, and lead product development and commercialization. Prof. van der Poll and his team will lead publication of the collaboration's findings and continue the commercially-oriented research and development directions of the MARS (Molecular Diagnosis and Risk Stratifications of Sepsis) Consortium, a trial of over 7,500 ICU patients with sepsis or at risk of developing sepsis. As a first step, Immunexpress and Prof. Tom van der Poll and his team jointly published in December last year in PLoS Medicine the preliminary clinical validation studies of the SeptiCyte™ LAB biomarkers.
Immunexpress is a Seattle-based molecular diagnostic company committed to improving outcomes for patients with sepsis and suspected of sepsis. Immunexpress's SeptiCyte™ technology quantifies directly from whole blood specific molecular markers from the patient's own immune system – the "host response." Detecting the host's septic immune response has the potential to identify sepsis earlier, faster and more accurately than current sepsis diagnostics that focus on identifying the invading pathogen; the host response is independent of whether or not the pathogen is in the blood sample. Immunexpress's pipeline includes assays for readily available lab-based platforms, as well as point-of-care (POC) sample-to-answer instrumentation. For more information visit www.Immunexpress.com.
About the Academic Medical Center at the University of Amsterdam
The Academic Medical Center (AMC) is one of the foremost research institutions in the Netherlands, as well as one of its largest hospitals. AMC has 45 clinical and research departments and houses all medical specializations. Over 8500 people work here to provide integrated patient care, fundamental and clinical scientific research, and teaching. The AMC complex houses the university hospital and the faculty of medicine of University of Amsterdam as well as the Emma Children's Hospital, the Netherlands Institute for Neuroscience, the medical department of the Royal Tropical Institute, the Amsterdam Institute for Global Health and Development, and the Spinoza Centre for Neuroimaging. AMC is one of the Netherlands' trauma centers. A number of biotech companies – some of them AMC spin-offs – are also located on the premises. This concentration of expertise provides a breeding ground for fruitful scientific collaboration.
For more information please visit https://www.amc.nl/web/Research.htm.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immunexpress-and-academic-medical-center-to-collaborate-on-development-of-sepsis-related-biomarker-panels-300253492.html
SOURCE Immunexpress Inc.